Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Paradigm Biopharmaceuticals ( (AU:PAR) ) just unveiled an announcement.
Paradigm Biopharmaceuticals has reached a significant milestone in its Phase 3 clinical trial for iPPS, a treatment for knee osteoarthritis, by dosing participants in both the United States and Australia. The trial, which aims to evaluate the efficacy and safety of iPPS, has shown improved screening results due to refined eligibility criteria guided by the FDA. With nearly all sites expected to be activated by the end of October, the company is on track to meet its enrolment targets and deliver an interim analysis by mid-2026, potentially impacting its market position and stakeholder value.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on improving patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. The company is currently developing injectable pentosan polysulfate sodium (iPPS) for treating diseases where inflammation plays a major pathogenic role, such as osteoarthritis and mucopolysaccharidosis.
Average Trading Volume: 870,084
Technical Sentiment Signal: Sell
Current Market Cap: A$123.5M
For detailed information about PAR stock, go to TipRanks’ Stock Analysis page.